{
  "question": "What are the small molecules that will form some kind of protein-ligand interactions with the chemical represented by ChEMBL ID: CHEMBL4803817?\nOnce you feel you are ready for the final answer, directly return the answer with the format <<<answer content>>> at the end of your response, e.g. <<<C>>>, <<<9.8>>>.",
  "response_list": [
    "### Small Molecules Targeting SARS-CoV-2 Nsp14 Protein Identified\n\nA variety of small molecules have been identified as interacting with the protein represented by ChEMBL ID: CHEMBL4803817, which is the SARS-CoV-2 non-structural protein 14 (Nsp14). This protein has two enzymatic activities crucial for the virus: a 3'-to-5' exoribonuclease (ExoN) activity and an N7-methyltransferase (N7-MTase) activity. The small molecules that interact with Nsp14 are primarily inhibitors targeting its methyltransferase function, which is vital for the stability and translation of viral RNA.\n\nA range of inhibitors has been developed and studied:\n\n*   **S-adenosyl-l-homocysteine (SAH) Analogues:** Researchers have designed novel derivatives of SAH, a natural product of the methylation reaction, that act as inhibitors. These were developed using a homology model of SARS-CoV-2 Nsp14 based on the structure of its SARS-CoV counterpart. One particularly potent inhibitor from this class is **12q (STM969)**, which has shown an IC50 of 19 nM, making it one of the most active Nsp14 inhibitors reported.\n\n*   **Adenosine 5'-Carboxamide Derivatives:** A series of these derivatives have been synthesized, with coumarin analogues being particularly effective. Among these, compound **18l (HK370)** demonstrated high selectivity and favorable properties in laboratory tests.\n\n*   **Non-SAM-like Inhibitors:** Through large-scale docking strategies, several novel chemotypes that do not resemble S-adenosyl methionine (SAM), the methyl donor for the Nsp14 MTase, have been discovered. These efforts have yielded inhibitors with IC50 values in the low micromolar range.\n\n*   **Covalent Inhibitors:** A strategy involving the docking of a library of electrophiles led to the discovery of inhibitors that covalently modify Cys387 in the SAM binding site of Nsp14.\n\n*   **Virtually Screened Compounds:** Computational methods have been employed to screen large libraries of molecules. One such study identified nine potential inhibitors, with compounds **A1, A2, and A3** showing significant inhibition of the N7-MTase activity in subsequent biochemical assays.\n\n*   **First-in-Class Non-covalent Inhibitors:** A high-throughput screening campaign identified **RU-0415529**, a non-covalent inhibitor that forms a ternary complex with S-adenosylhomocysteine (SAH). Optimization of this hit compound led to the development of **TDI-015051**, which exhibited potent inhibition of viral replication in cell-based assays and a mouse model of SARS-CoV-2 infection.\n\nThese small molecules represent various chemical starting points for the development of antiviral therapies targeting the essential functions of the SARS-CoV-2 Nsp14 protein."
  ],
  "user_prompt_list": [
    "What are the small molecules that will form some kind of protein-ligand interactions with the chemical represented by ChEMBL ID: CHEMBL4803817?\nOnce you feel you are ready for the final answer, directly return the answer with the format <<<answer content>>> at the end of your response, e.g. <<<C>>>, <<<9.8>>>."
  ],
  "system_message": ""
}